BELUMOSUDIL (Rezurock®)
Clinical Indication
For treating chronic graft-versus host disease after 2 or more systemic treatments in people 12 years and over.
Date of classification
March 2024
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.